Search
Dexamethasone Treatment Options
A collection of 1455 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
913 - 924 of 1455
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
Completed
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL).
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/28/2019
Locations: City of Hope National Medical Center, Duarte, California +21 locations
Conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
Withdrawn
This study will evaluate the safety and preliminary efficacy of venetoclax when combined with lenalidomide and dexamethasone for participants with newly diagnosed, active t(11;14) positive multiple myeloma (MM).
This study will consist of 2 parts: Part 1 Dose Escalation and Part 2 Dose Expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2019
Locations: City of Hope /ID# 212211, Duarte, California +21 locations
Conditions: Multiple Myeloma
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
Completed
The primary objective of this study is to evaluate the efficacy and safety of induction therapy R-ICE in comparison to R-DHAP after 3 cycles adjusted to successful mobilization of stem cells in patients with previously treated diffuse large B-cell lymphoma CD20.
The goal is to detect a difference in mobilization adjusted response rate of 15% between R-ICE and R-DHAP.
The other objective is to evaluate the efficacy and safety of MabThera maintenance therapy after transplantation as measured by... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/22/2019
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +9 locations
Conditions: Lymphoma, Large-Cell, Diffuse
Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Withdrawn
This research study is studying a combination of drugs as a possible treatment for multiple myeloma.
The drugs that will be administered are:
* ABI-009 (nab-rapamycin)
* Pomalidomide
* Dexamethasone
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2019
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Multiple Myeloma
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Terminated
RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Sorafenib and lenalidomide may also stop the growth of cancer cells by blocking blood flow to the cancer. Giving so... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/12/2019
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer
Completed
This pilot research trial studies folate receptor in diagnosing ovarian cancer using serum samples from patients with a newly diagnosed pelvic mass or previously diagnosed ovarian cancer. Studying samples of serum from patients with ovarian cancer in the laboratory may help understand the use of folate receptor induction as a clinical tool in initial diagnosis, surveillance, and recurrence.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/12/2019
Locations: Karmanos Cancer Institute at McLaren Bay Region, Bay City, Bay City, Michigan +1 locations
Conditions: Adnexal Mass, Borderline Ovarian Epithelial Tumor, Ovarian Clear Cell Tumor, Ovarian Endometrioid Tumor, Ovarian Neoplasm, Ovarian Serous Tumor, Recurrent Ovarian Carcinoma
The Adrenal Contribution to Androgen Production in Girls During Puberty
Completed
In girls with elevated androgens the precise source of androgen excess throughout puberty and early adolescence has not been carefully examined. The investigators propose to examine whether the adrenal gland produces the majority of androgens during puberty by studying the differences in androgen responses to adrenocorticotropin hormone (ACTH) administration in normal weight (NW) and obese (OB) girls ages 7-18. The investigators' analyses will compare steroid changes before and 60 min after ACTH... Read More
Gender:
FEMALE
Ages:
Between 7 years and 18 years
Trial Updated:
08/08/2019
Locations: University of california, san diego, La Jolla, California
Conditions: Development
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Completed
The purpose of this study is to identify a safe and tolerable dose of BMS-906024, either alone or in combination with Dexamethasone in subjects with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma who no longer respond to or have relapsed from standard therapies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2019
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +5 locations
Conditions: Lymphoblastic Leukemia, Acute T-cell, Precursor T-Cell Lymphoblastic Lymphoma
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
Completed
This study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of humanized anti-EGFR monoclonal antibody, HLX07, in patients with epithelial cancer who have failed standard therapy and deemed unamenable by conventional therapy. This study will also evaluate the pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumor effect of HLX07 and explore the potential prognostic and predictive biomarkers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2019
Locations: Henlix, Inc., Fremont, California +1 locations
Conditions: Solid Tumour
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma.
PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/24/2019
Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama +175 locations
Conditions: Lymphoma
Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction
Completed
Subjects are being asked to participate in this study because they will be undergoing unilateral (one) or bilateral (two) mastectomy surgery with immediate reconstruction involving insertion of a tissue expander.
Gender:
FEMALE
Ages:
Between 18 years and 79 years
Trial Updated:
07/24/2019
Locations: Northwestern University, Chicago, Illinois
Conditions: Breast Cancer
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Terminated
This is a phase II study designed to investigate the combination of bortezomib with the mitoxantrone reinduction regimen used in the ALL R3 trial. The study will enroll patients with high risk ALL relapse including early bone marrow relapse and second or greater relapse of any kind. Patients with relapsed LL will also be eligible. Bone marrow evaluation will be performed after blood counts recover to assess the rate of CR (\<5% bone marrow blasts) and MRD status in children following this regime... Read More
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
07/23/2019
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
913 - 924 of 1455